Adenoid cystic carcinoma: Use of cell proliferation, bcl-2 expression, histologic grade, and clinical stage as predictors of clinical outcome

Head and Neck

Volumn 22, Issue 5, 2000, Pages 489-497

  Norberg Spaak, Lena ^a   Dardick, Irving ^b   Ledin, Torbjörn ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical outcome; Grading and stage; Proliferation; Salivary gland tumors

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; APOPTOSIS; CARCINOMA, ADENOID CYSTIC; CAUSE OF DEATH; CELL CYCLE; CELL DIVISION; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HEAD AND NECK NEOPLASMS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0033942630     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0347(200008)22:5<489::AID-HED8>3.0.CO;2-X     Document Type: Article

References (32)

1. Szanto PA, Luna MA, Tortoledo E, White RA. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer 1984;54:1062-1069.
2. Batsakis JG, Luna MA, el-Naggar A. Histopathologic grading of salivary gland neoplasms: III. Adenoid cystic carcinomas. Ann Otol Rhinol Laryngol 1990;99:1007-1009.
3. Hamper K, Lazar F, Dietel M, et al: Prognostic factors for adenoid cystic carcinoma of the head and neck: A retrospective evaluation of 96 cases. J Oral Pathol Med 1990; 19:101-107.
4. Zhang H, Yousem SA, Franklin WA, Elder E, Landreneau R, Ferson P, Keenan R, Whiteside T, Levitt ML: Differentiation and programmed cell death-related intermediate biomarkers for the development of non-small cell lung cancer: A pilot study. Hum Pathol 1998;29:965-971.
5. Regezi JA, McMillan A, Dekker N, Daniels TE, Silverman Jr S, Schoelch M, Ziober BL: Apoptosis-associated proteins in oral lymphomas from HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont 1998; 86:196-202.
6. Skalova A, Leivo I. Cell proliferation in salivary gland tumors. Gen Diagn Pathol 1996;142(1):7-16.
7. Zhao M, Zhao QX, Saitoh M, Ohmura H, Okamoto Y, Shrestha P, Mori M. Proliferating patterns of salivary gland adenocarcinomas with the use of PCNA labeling. Anticancer Res 1996;16(5A):2693-2698.
8. Tytor M, Gemryd P, Grenko R, Lundgren J, Lundquist PG, Nordenskjöld B. Adenoid cystic carcinoma: Significance of DNA Ploidy. Head Neck 1995;17:319-327.
9. Hellquist HB, Sundelin K, Di Bacco A, Tytor M, Manzotti M, Viale. Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki67 and bcl-2 expression and of in situ end labelling (TUNEL). J Pathol 1997;181:323-329.
10. Singh BB, Chandler Jr FW, Whitaker B, Forbes-Nelson AE. Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont 1998;85:692-698.
11. Lu Q-L, Elia G, Lucas S, Alero TJ. Bcl-2 proto-oncogene expression in Epstein-Barr virus-associated nasopharyngeal carcinoma. Int J Cancer 1993;53:29-35.
12. Palazzo JP, Kafka NJ, Grasso L, Chakrani F, Hanau C, Cuesta KH, Mercer WE. The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma. Hum Pathol 1997;28:1189-1195.
13. Fleming MV, Guinee Jr DG, Chu WS, Freedman AN, Caporaso NE, Bennett WP, Colby TV, Tazelaar H, Abbondanzo SL, Jett J, Pairolero P, Trastek V, Liotta LA, Harris CC, Travis WD. Bcl-2 immunohistochemistry in a surgical series on non-small lung cancer patients. Hum Pathol 1998;29:60-64.
14. Rakozy C, Grignon DJ, Sarkar FH, Sakr WA, Littrup, Forman J. Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. Mod Pathol 1998;11:892-899.
15. American Joint Committee on Cancer. Manual for staging of cancer. 3rd ed. Philadelphia: American Joint Committee; 1988.
16. Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg 1992;164:623-628.
17. Perzin KH, Gullane P, Clairmont AC. Adenoid cystic carcinomas arising in salivary glands. A correlation of histologic features and clinical course. Cancer 1978;42: 265-282.
18. Ellis GL, Auclair PL. Atlas of tumor pathology. Tumors of the salivary gland. Third series, Fascicle 17. Washington DC; Armed Forces Institute of Pathology; 1996. p 203.
19. Kelsch RD, Bhuiya T, Fuchs A, Gentile P, Kahn MA, Fantasia JE. Polymorphous low-grade adenocarcinoma: flow cytometric, p53, and PCNA analysis. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, Endodontics 1997;84(4):391-399.
20. Yang L, Liu B, Qin C, Hashimura K, Yamada T, Sumitomo S, Mori M. Comparison of proliferating nuclear antigen index in benign and malignant salivary pleomorphic adenoma. Eur J Cancer. Part B Oral Oncol 1994;30B(1): 56-60.
21. Norberg L, Stratis M, Dardick I. Quantitation and localization of cycling tumor cells in pleomorphic adenomas and myoepitheliomas: an immunohistochemical analysis. J Oral Pathol Med 1997;26:124-128.
22. Ogawa I, Miyauchi M, Takata T, Vuhahula E, Ijuhin N, Nikai H. Proliferative activity of salivary gland pleomorphic adenomas and myoepitheliomas as evaluated by the proliferating cell nuclear antigen PCNA) labeling index (LI). J Oral Pathol Med 1993;22:447-450.
23. Felix A, El-Naggar AK, Press MF, Ordonez NG, Fonseca I, Tucker SL, Luna MA, Batsakis JG. Prognostic significance of biomarkers (c-erB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 1996;27(6):561-566.
24. Cho KJA, El-Naggar AK, Ordonez NG, Luna MA, Austin J, Batsakis JG. Epithelial-myoepithelial carcinoma of the salivary glands. A clinicopathologic, DNA flow cytometric, and immunohistochemical study of Ki-67 and Her-2/neu oncogene. Anat Pathol 1994:103(4);432-437.
25. Fonseca I, Soares J. Epithelial-myoepithelial carcinoma of the salivary glands. A study of 22 cases. Virchows Arch A Pathol Anat 1993;422:389-396.
26. Soini Y, Tormanen U, Paakko P. Apoptosis is inversely related to bcl-2 but not to bax expression in salivary gland tumours. Histopathology 1998;32:28-34.
27. Burford-Mason AP, Mackay A, Cummins M, Dardick I. Detection of proliferating cell nuclear antigen (PCNA) in paraffin-embedded specimens is dependent on pre-embedding tissue handling and fixation. Arch Pathol Lab Med 1994;118;1007-1013.
28. Kamio N. Coexpression of p53 and c-erB-2 proteins is associated with histological type, tumor stage, and cell proliferation in malignant salivary gland tumors. Virchows Arch 1996;428(2):75-83.
29. Nordgard S, Franzen G, Boysen M, Halvorsen TB. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Laryngoscope 1997;107:531-536.
30. Skalova A, Simpson RH, Lehtonen H, Leivo I. Assessment of proliferative activity using the MIB-1 antibody helps to distinguish polymorphous low-grade adenocarcinoma from adenoid cystic carcinoma of salivary glands. Pathol Res Pract 1997;193:695-703.
31. Zhu QR, White FH, Tipoe GL. p53 oncoprotein accumulation in adenoid cystic carcinoma of parotid and palatine glands. Pathology 1997;29:154-158.
32. Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM. Expression and mutations of p53 in salivary gland tumors. J Oral Pathol Med 1997;26:217-223.